LGLais Lopes Almeida Gomes

Lais Lopes Almeida Gomes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lais Lopes Almeida Gomes has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multidisciplinary Support for Children With Genodermatoses in Brazil: A RE ‐ AIM Evaluation of Casa Santa Teresinha's Community‐Based Model

    by Izadora Lapenda, Alreem Al‐Nabti, Natalia Campacci, Zilda Najjar Prado de Oliveira, Luciana Paula Samorano, Lais Lopes Almeida Gomes, Magda Carneiro‐Sampaio, Regia Patriota

    Genodermatoses impose substantial psychosocial and functional burdens on affected children and their families, yet structured community‐based support models remain underrepresented in the literature. We describe Casa Santa Teresinha , a Brazilian non‐profit organization providing multidisciplinary care for children with genodermatoses and present a programmatic evaluation using the RE‐AIM framework (Reach, Effectiveness, Adoption, Implementation, and Maintenance). In 2025, the program engaged 103 patients and their families, delivering 4419 service encounters across psychology, social work, physiotherapy, genetic nursing, nutrition, and socioeducational activities. The model integrates individualized care planning, a genetic nurse acting as patient navigator, and innovative strategies to address social determinants of health, including rideshare‐based transportation as a clinical safety measure. Strong engagement and sustained participation highlight the program's relevance in a socioeconomically vulnerable population. While formal outcome measures are being implemented, this evaluation demonstrates a scalable, community‐based model that complements hospital care and may inform similar initiatives globally.

  • Mycoplasma Rash With Eosinophilia and Systemic Symptoms: A Report of Two Cases

    by Lais Lopes Almeida Gomes, Drew Mitchell, Nehal J. Shah, Morgan Greenfield, James R. Treat

    Mycoplasma pneumoniae is a common cause of community‐acquired pneumonia in school‐aged children. Various cutaneous reactions to M. pneumonia have been described, including reactive infectious mucocutaneous eruption, morbilliform eruptions, and vasculitis. This study highlights two cases of Mycoplasma infection that presented with a morbilliform eruption and had clinical and laboratory findings similar to drug reaction with eosinophilia and systemic symptoms (DRESS), a pattern not well documented in the literature, and emphasizes the clinical manifestations that help distinguish between these conditions.

  • Top Cited Papers

    2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus

    by Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'ERa, Alí Duarte‐García, Linda T. Hiraki, Mary Beth F. Son, Victoria P. Werth, Cynthia Aranow, April Barnado, et al.

    Objective: To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. Methods: Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. Results: We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities. Conclusion: This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.


  • Top Cited Papers

    2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus

    by Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'ERa, Alí Duarte‐García, Linda T. Hiraki, Mary Beth F. Son, Victoria P. Werth, Cynthia Aranow, April Barnado, et al.

    Objective: To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. Methods: Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. Results: We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities. Conclusion: This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.


  • Normal muscle enzyme levels in classic dermatomyositis: implications for clinical trial endpoints

    by Aretha On, Shae Chambers, Hammad Ali, Catherine Shen, Touraj Khosravi-Hafshejani, Lais Lopes Almeida Gomes, Xiwei Yang, Victoria P Werth

    Muscle involvement in dermatomyositis can present without muscle enzyme elevations in 26–48% of patients. These findings are important to acknowledge in order to interpret muscle enzyme testing within the broader clinical context.

  • Open Access

    Isolated scleroderma of the lower extremities misdiagnosed as lymphedema and presenting with scleroderma renal crisis

    by Hammad Ali, Lais Lopes Almeida Gomes, Touraj Khosravi-Hafshejani, Aretha On, Xiwei Yang, Shae Chambers, Victoria P. Werth

    Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by progressive fibrosis, vasculopathy, and immune dysregulation. The disease commonly presents with Raynaud’s phenomenon and skin thickening, commonly of the upper limb. Isolated lower extremity presentation is uncommon and often misdiagnosed. This diagnostic uncertainty may lead to delayed recognition and increased morbidity, particularly when SSc mimics lymphedema in the early stages. We report a case of a 61-year-old female who initially presented with lower extremity swelling and was misdiagnosed with primary lymphedema. Despite treatment with diuretics and compression therapy, her symptoms progressed to involve her upper extremities, prompting further evaluation. Physical examination revealed non-pitting lower extremity scleroderma, sclerodactyly, puffy hands, and nailfold capillary abnormalities. Laboratory workup was positive for anti-RNA polymerase III antibodies, a marker associated with an increased risk of scleroderma renal crisis. The patient developed scleroderma renal crisis after a delayed diagnosis, necessitating hospital admission and initiation of angiotensin-converting enzyme inhibitors. This case highlights the challenges in distinguishing early lower extremity SSc from lymphedema. Early identification of atypical SSc presentations is critical to be cognizant of life-threatening complications such as scleroderma renal crisis. Clinicians should maintain a high index of suspicion for SSc in patients with persistent non-pitting lower extremity swelling, skin thickening, and abnormal capillaroscopy findings, even in the absence of initial upper limb involvement.

  • Open Access

    Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study

    by Caroline J. Stone, Geeta Ahuja, Lais Lopes Almeida Gomes, Joy Poroye, Daniella Forman Faden, Lillian Xie, Rui Feng, Barbara White, Victoria P. Werth


  • Open Access

    Prevalence and Risk of Immunostimulatory Herbal Supplement Treatment Among Autoimmune Dermatology Patients

    by Daniella F. Faden, Caroline J. Stone, Lillian Xie, Lais Lopes Almeida Gomes, Victoria P. Werth

    Objective: We assess the prevalence and patterns of herbal supplement treatment among patients with autoimmune skin diseases, particularly dermatomyositis (DM) and cutaneous lupus erythematosus (CLE), and identify commonly taken supplements and their associated risks.Methods: This study screened 673 adult patients with clinicopathologic evidence of DM or CLE at the University of Pennsylvania's rheumatologic‐dermatology clinic between January 2007 and February 2024. Demographic data, disease characteristics, and detailed information on herbal supplement treatment were collected. Predictors of supplement treatment were analyzed using chi‐square tests and reported as odds ratios.Results: The prevalence of herbal supplement treatment was 32% among the cohort. The relative frequency of herbal supplement treatment was significantly higher in younger patients (44% of patients ages 18–29 years, reference; 29% ages 50–64 years, P = 0.02; 23% ages ≥65 years, P = 0.003) and in Hispanic/Latino patients (58% vs 31% White, P = 0.009). No significant difference in herbal supplement treatment was seen by sex (33% of female participants, 29% of male participants, P = 0.49), race (31% White, P = reference; 31% Black, P = 1.0; 38% Asian, P = 0.55), or disease (30% of patients with DM, 36% of patients with CLE; P = 0.12). Among patients with DM, 31% experienced a disease onset or exacerbation after supplement treatment compared with 10% of patients with CLE. Elderberry treatment was associated with the highest risk of exacerbation in both disease cohorts (62% DM, 50% CLE).Conclusion: Herbal supplement treatment is prevalent among patients with autoimmune skin diseases, with immunostimulatory supplements posing a significant risk for immune dysregulation, particularly in DM. Providers should proactively screen and counsel patients regarding treatment with these supplements.


  • Safety and efficacy of topical nitric oxide‐releasing berdazimer gel for molluscum contagiosum clearance: A systematic review and meta‐analysis of randomized controlled trials

    by Izabela Pera Calvi, Isabela R. Marques, Sara A. Cruz, Yasmin Luz Lima Mesquita, Eduardo M. H. Padrao, Rafaela M. Souza, Andrew Brown, Danielle G. V. Caçador, Lidia M. Poppe, Lais Lopes Almeida Gomes

    Molluscum contagiosum (MC) is a contagious infection that, although benign, can become an aesthetic burden and lead to other opportunistic infections, secondary dermatitis, and self‐isolation. Currently, several treatment options are available for MC, including the newly investigated nitric oxide‐releasing berdazimer gel, leading this review to evaluate randomized controlled trials (RCT) comparing berdazimer gel with a vehicle for treating MC. The meta‐analysis included three reports and four RCT involving 1854 patients, with 1106 (59.6%) randomized to receive berdazimer. Our findings suggest that berdazimer is effective in the management of MC lesions, but the increased clearance of lesions and reduction of scarring must be weighed against the potential for topical adverse effects, particularly when considering the use of this therapy in pediatric patients.